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ABSTRACT
Background: There is variation in uptake of  in vitro fertilisation (IVF) between countries, and 
Australia has high incidence rates of  IVF due to universal public funding. However, it remains unclear 
whether there is regional variation and, if  present, what might cause this.
Objectives: We sought to determine whether regional variations in treatment rates existed and what 
might influence these.
Methods: The number of  cycles of  fresh IVF and intrauterine insemination (IUI) for women were 
obtained for the period 2011 until 2014 in two age groups (25 to 34 years and 35 to 44 years) to calculate 
incidence rates. Proxy indicators that might influence treatment affordability were: unemployment 
rates; average weekly total earnings; coverage of  private health insurance; and, percentage of  women 
in the highest socioeconomic quintile. Measures of  accessibility considered were percentage of  the 
population remote from urban areas and average state population density. Linear regressions were 
performed using log-transformed ratio of  IVF and IUI incidence rates.
Results: Variations were found in IVF uptake between states with greater differences in older women. 
There was no significant association between IVF procedures and population density or geographic 
isolation. Economic factors were not associated with IVF uptake.
Conclusion: These findings suggest that factors such as physician preference, clinical practice 
guidelines, and cryopreservation protocols of  ART units might explain the national variation in uptake 
of  IVF.
Keywords: Assisted reproductive technology, IVF, clinical variation, socio-economic factors, access, 
health economics
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BACKGROUND
Assisted reproductive technology (ART) has advanced in scope and success rate over more than 30 years and 
has widespread availability in many countries now. In 2013 in Australia 4.4% of  all births were the result of  
ART, the majority in women having their first child1: that rate is similar to other developed countries.2 Despite 
the acceptance and uptake of  ART there remains variation in its use internationally and it is recognised that 
many factors influence the rate of  ART usage in different parts of  the world.3 While some influences such as 
public funding of  in vitro fertilisation (IVF) treatment are relatively easy to study quantitatively other factors, in 
particular socio-religious and cultural influences, have not been extensively investigated. In addition, the rate 
of  ART uptake is likely to vary according to physician preference, national or jurisdictional guidance regarding 
indications for treatment, and also the results of  individual ART units and practices regarding cryopreservation.
In Australia, where both IVF and intrauterine insemination (IUI) receive public funding, there currently is no 
limit on the number of  cycles that can be funded and no clinical eligibility criteria associated with public funding. 
Thus Australia fares well in terms of  the affordability of  ART for patients compared to many other countries, 
fostering a high proportion of  IVF cycles that culminate in single embryo transfer (SET).3 At present there 
are no national guidelines regarding clinical indications for the use of  IVF in Australia, and de-identified data 
regarding live birth rates for non-donor cycles using fresh embryo transfers are published to allow comparision 
of  the performance of  ART clinics.4 In view of  the potential differences in indications, clinical practices, and 
outcomes for IVF we set out to determine whether there were associated differences in IVF uptake a regional 
level in Australia.
METHODS
Because of  universal health funding through Medicare Australia, all Australian citizens and permanent residents 
are eligible for a financial rebate for IVF procedures and intrauterine insemination (IUI) cycles. To ascertain 
the number of  cycles of  fresh IVF and IUI, we used data from the Medical Benefits Schedule (MBS) statistical 
database for the four-year period from January 2011 until December 2014. These data were consolidated into 
two age groups for women – 25 to 34 years of  age (the ‘younger age group’), and 35 to 44 years (the ‘older age 
group’) – for the largest five states in Australia (New South Wales, Victoria, Queensland, Western Australia, and 
South Australia). It is important to note that there is no difference in eligibility of  women to receive funding 
from Medicare Australia between any state in Australia. To specify stimulated IVF cycles we used the MBS item 
number for oocyte retrieval (13212), and for IUI cycles we used the MBS item number for IUI (13203). To 
provide denominators for calculation of  procedural incidence rates we obtained point estimates of  the total 
female population of  each age group in each of  the five states from the Australian Bureau of  Statistics (ABS) 
for each year of  the study.
Because Medicare funds a proportion, but not all, of  the cost of  treatment for both IVF and IUI cycles most 
women will have to pay an out-of-pocket cost. There is thus a potential for affordability of  IVF and IUI to 
vary according to socio-economic factors from two aspects: economic ability for IVF; and, geographical access. 
We considered four potential proxy indicators for the economic ability for IVF in each state as: (1) state-level 
unemployment rate; (2) average weekly total earning per person; (3) the proportion of  the population with 
private health insurance; and, (4) the percentage of  women aged 30 to 49 years in the top 20% of  Socio-
Economic Indexes for Areas (SEIFA).5 As they would impact on affordability, we hypothesised that lower rates 
of  unemployment, higher average weekly earnings, a higher proportion of  the population with private health 
insurance and a higher percentage of  the population in the top 20% SEIFA would be associated with a higher 
uptake of  IVF procedures.
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Since most ART units are located in capital cities or large regional centres, we also considered relative accessibility 
by using two factors: the percentage of  the population residing outside of  capital city and significant urban 
areas (‘geographic isolation’) and averaged each state population density per squarekilometre. We hypothesised 
that a higher percentage of  the population living outside of  capital city and significant urban areas and a lower 
population density to translate into lower uptake of  IVF procedures as access would be more difficult. The 
socio-economic data were calculated from the relevant ABS datasets: ABS 6202.0 - Labour Force, Australia6; 
ABS 6302.0 - Average Weekly Earnings, Australia7; ABS 3101.0 - Australian Demographic Statistics8; ABS 3218.0 - 
Regional Population Growth9; The Private Health Insurance Administration Council annual coverage report10; and, 
a customised data set obtained from the ABS. The study received approval from the Human Research Ethics 
Committee of  the Australian National University (protocol 2015/347).
Statistical Analyses
Data were extracted to Excel™ spreadsheets and statistical analysis was performed in GenStat and SPSS. Since 
there are no national guidelines regarding the indications for either IUI or IVF, we hypothesised that in some 
cases there would be a substitution of  IUI cycles for IVF and took this into account in the analysis. The effect 
of  each of  the socio-economic factors was examined separately using linear regressions on the ratio of  incident 
rates of  oocyte retrievals and intrauterine insemination, indicating the possible substitution of  IUI procedures 
over IVF. The analyses used log-transformed ratio data to satisfy the homogeneity of  the variance assumption 
for linear regression.
RESULTS
Our analysis was divided into two parts: firstly, to review the incidence rates of  IVF and IUI in Australia from 
2011 to 2014, separating women in the younger and older age groups. Secondly, we examined the effects of  the 
socio-economic factors measuring affordability and remoteness/population density as measures of  accessibility.
There were marked variations in the incidence rate of  stimulated IVF cycles (oocyte retrievals per 1000 women 
per year) between the five states in both the younger (Figure 1) and older (Figure 2) age groups, with greater 
differences found in the older age group. The between-state variations in incidence rates of  IUI cycles were 
even greater, but of  similar magnitude in both the younger and older cohorts (Figures 3 and 4). Taking into 
account the possibility of  a substitution of  IUI for IVF in some women, Figure 5 demonstrates the trend of  
IVF over IUI at state level and the national level in both age groups: as expected the incidence rate of  IVF was 
higher in the older age group in all five states. Across both the younger and older cohorts the highest uptake 
rates were in the states of  Victoria and South Australia. Table 1 shows detailed age-stratified incidence rates of  
IVF and IUI. It was notable that, compared to the IVF incidence rates, uptake of  IUI showed much greater 
variation between the states. Over the study period the incidence rates of  both IVF and IUI remained relatively 
stable in other states, there was a notable increase in the IVF incidence rate in South Australia in 2013 (a 1.72 
increase in the younger age group and a 3.38 increase in the older age group). South Australia had the lowest 
incidence rates of  IUI compared to other states during the study period.
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Figure 1. Age-stratified incidence rate of  in vitro fertilisation (IVF) cycles proceeding to oocyte retrieval in 
women aged 24 to 35 years in Australia (oocyte retrieval procedures per 1000 women per year), 2011 to 2014 
inclusive
[NSW – New South Wales, Vic – Victoria, Qld – Queensland, WA – Western Australia, SA – South Australia. Overall national 
incidence rate for Australia as black dashed line]
Figure 2. Age-stratified incidence rate of  in vitro fertilisation (IVF) cycles proceeding to oocyte retrieval in 
women aged 35 to 44 years in Australia (oocyte retrieval procedures per 1000 women per year), 2011 to 2014 
inclusive
[NSW – New South Wales, Vic – Victoria, Qld – Queensland, WA – Western Australia, SA – South Australia. Overall national 
incidence rate for Australia as black dashed line]
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Figure 3. Age-stratified incidence rate of  intrauterine insemination (IUI) cycles in women aged 24 to 34 years 
in Australia (cycles per 1000 women per year), 2011 to 2014 inclusive
[NSW – New South Wales, Vic – Victoria, Qld – Queensland, WA – Western Australia, SA – South Australia. Overall national 
incidence rate for Australia as black dashed line]
Figure 4. Age-stratified incidence rate of  intrauterine insemination (IUI) cycles in women aged 35 to 44 years 
in Australia (cycles per 1000 women per year), 2011 to 2014 inclusive
[NSW – New South Wales, Vic – Victoria, Qld – Queensland, WA – Western Australia, SA – South Australia. Overall national 
incidence rate for Australia as black dashed line]
JHEORRawlings L, et al.
21JHEOR 2017;5(1):16-26 | www.jheor.org
Figure 5. Age-stratified ratio of  IVF cycles versus intrauterine insemination IUI cycles in women (a) aged 25 
to 34 years and (b) aged 35 to 44 years in Australia, 2011 to 2014 inclusive
[NSW – New South Wales, Vic – Victoria, Qld – Queensland, WA – Western Australia, SA – South Australia. Overall national 
incidence rate for Australia as black dashed line]
Results from linear regressions (Table 2) directly compare the association between the potentially influential socio-
economic factors and the uptake of  IVF procedures. The directional relationships between the socioeconomic
factors and the uptake of  IVF were consistent in both age groups across the study period. With respect to 
geographical access to ART units there was no significant association in either age group between the incidence 
rate of  IVF procedures and population density or geographic isolation (p = 0.31 for women in the younger 
age group, and p = 0.12 for women in the older age group). While the overall state population density was not 
significantly associated for younger women it was positively related to the uptake of  IVF for older women.
In terms of  the affordability for IVF most of  the factors studied did not show a significant association with 
the uptake of  IVF in either age group. Counterintuitively, in the younger age group a higher percentage of  
population holding private health insurance was significantly associated with a lower uptake of  IVF procedures 
(p = 0.043). However, the negative relationship appeared to be driven by the high level of  private health 
insurance coverage and low uptake of  IVF in Western Australia.
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Table 1. Age-stratified incidence rates of  in vitro fertilisation cycles proceeding to oocyte retrieval and 
intrauterine insemination cycles (cycles per 1000 women per year) from 2011 to 2014 for women in two age 
groups: 25 to 34 years and 35 to 44 years
in vitro fertilisation (cycles per 1000 women)
NSW VIC QLD SA WA National
25-34 2011 7.79 8.58 7.27 7.41 6.23 7.69
2012 8.01 8.39 8.51 7.57 6.51 8.00
2013 8.19 7.71 8.11 9.29 6.01 7.87
2014 6.07 7.19 7.08 8.56 5.57 6.75
35-44 2011 14.45 15.97 9.73 9.98 10.32 13.56
2012 14.59 17.69 10.85 9.89 9.60 13.72
2013 15.57 16.72 10.77 13.27 9.90 14.02
2014 15.46 17.31 11.21 10.47 10.64 14.13
Intrauterine Insemination (cycles per 1000 women)
NSW VIC QLD SA WA National
25-34 2011 2.26 2.07 6.83 1.08 3.97 3.23
2012 2.53 2.09 6.26 1.94 3.85 3.28
2013 2.25 1.74 5.60 2.26 3.18 2.92
2014 2.27 1.55 4.48 1.48 3.13 2.57
35-44 2011 2.56 1.92 5.29 1.04 3.68 2.99
2012 2.59 2.01 4.67 1.27 3.16 2.90
2013 2.43 1.80 4.46 1.30 3.13 2.75
2014 2.70 2.08 4.50 1.68 3.20 2.93
Table 2. Regression analysis results of  effect of  socio-economic factors for women in two age groups: 25 to 
34 years and 35 to 44 years
25-34 35-44
estimate s.e. P values estimate s.e. P values
Geographical isolation -0.0444 0.0424 0.312 -0.0694 0.0424 0.123
Population density 0.0268 0.0133 0.061 0.0352 0.0128 0.015*
Total earnings -0.0345 0.0188 0.088 -0.0338 0.0207 0.125
Unemployment rates 0.273 0.212 0.218 0.306 0.220 0.186
Private health insurance -0.0551 0.025 0.043* -0.0507 0.0272 0.082
top 20% SEIFA 0.0237 0.0629 0.714 0.0103 0.0696 0.885
[* indicates the significance at 95% confidence level]
CONCLUSIONS
Although definitions vary, and precise population-based estimates are difficult to obtain, it is likely that in 
developed countries the prevalence of  ‘infertility’ is somewhere between 6.6 and 26.4%.11 In Australia it has been 
estimated that approximately one couple in six have experienced a delay of  greater than one year in achieving 
a planned pregnancy during their reproductive lives.12 For this reason infertility has become a significant public 
health issue with an accompanying increase in demand for ART.13
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This study suggests that there is considerable variation in the incidence rate of  IVF within Australia, and that 
this variation is not completely explained by a substitution with non-IVF ART procedures such as IUI, or 
by socio-economic influences such as geographical isolation from ART units or socio-economic factors that 
could impact on affordability of  treatment for couples. In Australia there is no over-arching national guidance 
regarding suitability or eligibility for IVF treatment, such as that published by NICE in the United Kingdom14: 
the choice of  treatment is largely a matter of  physician preference. Another factor that might be influential is 
the practice of  embryo cryopreservation.
The absolute need for IVF treatment is obviously difficult to estimate, and this need will be dependent upon the 
pregnancy rate of  treatment at a population level. However it has been estimated that at least 1500 IVF cycles 
per million people per year are needed to meet demand.15 The uptake of  IVF treatment does not correlate 
directly with clinical need, and there are marked differences in the incidence rate of  IVF treatments between 
developed countries.16 These differences have been attributed in large measure to the affordability of  treatment, 
and specifically policies of  public funding for ART.17
International comparative studies have revealed that, between countries, the average cost that patients pay for 
ART treatment relative to individual income is significantly associated with access to treatment.18 Australia has 
been used as exemplar of  supportive public funding of  IVF treatment,17 although it has been reported in other 
international studies that the number of  IVF clinics per reproductive-age woman is an independent predictor 
of  ART utilisation suggesting at least some degree of  ‘supplier-induced demand in the ART market.’18
In the absence of  clear guidance as to which women or couples ought to have IVF treatment, and a policy 
of  liberal access to funding of  IVF cycles, the optimal rate of  IVF uptake is difficult to measure. This is 
particularly so because of  the relative imprecision of  the definition of  ‘infertility’19: even with the use of  a 
definition for infertility of  ‘failure to conceive after one year,’ as many as 50% of  couples would be expected to 
become pregnant without treatment.20,21,22,23,24
An important principle of  public funding for health care in Australia is equity of  access, but from the Government 
perspective considerations of  cost-effectiveness are also relevant. There is evidence that decreasing affordability 
of  treatment is associated with a greater rate of  discontinuation of  treatment by women in older age groups, 
possibly due to poorer prognosis.18 The extent to which IVF treatment represents a valuable investment of  
public health resources has been subject to public debate in Australia.25 Ideally, cost-effectiveness studies should 
take into account the age of  the woman, the number of  cycles required to pregnancy, comparator treatments, 
and potential complications such as multiple and preterm birth. Fortunately, the multiple birth rate for IVF-
conceived pregnancies in Australia is less than 6% due to the high rate of  SET which is almost 80%.4 However 
it is recognised that SET will increase the number of  embryo transfer cycles required. Yet despite the low 
rate of  IVF-associated multiple birth in Australia there are increased odds for preterm birth and caesarean 
section (Box 1) both of  which increase the cost both of  birth and, for preterm birth, for longer-term care in 
childhood. Also, it has been noted that broader societal costs are underestimated commonly, including lost 
work productivity during treatment and the cost of  counselling and support.13
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Box 1. Proportions, odds ratios (OR) and 95% confidence intervals for preterm birth (stratified by gestation at 
birth) and caesarean delivery for IVF and non-IVF pregnancies in Australia in 2013. [*χ-square]
Data extracted from references [1] and [4].
Economies across the developed world are increasingly constrained fiscally and health expenditure sits within 
this environment. For example, in Australia health expenditure has increased from 6.5% of  gross domestic 
product (GDP) in 1989-90 to 9.7% of  GDP in 2013-14, with an increase in spending over that 25-year period 
from $50.3 billion to $154.6 billion in real terms.26 Australian Government support for IVF and other ARTs 
must be viewed in this context, and Government funding of  IVF raises questions for health economists.27 
Should limitations be placed on funding of  treatment in situations where there is a poor prognosis, such as older 
women? In certain circumstances, should funding for IVF only be available when treatments such as weight 
loss and lifestyle modification have been unsuccessful? If  fertility treatment is viewed as a ‘market’ then, in the 
absence of  outside pressure, the market will commonly work in the interest of  creating ‘new business.’ There 
may even be information asymmetry for patients seeking treatment to the point of  market failure warranting 
government intervention.
At present Australia has a good record of  achievement in ART and public funding of  IVF has benefitted tens of  
thousands of  families. However, it is important for all those involved in the provision of  IVF services to ensure 
that treatment is used appropriately and performed to the highest standards possible to avoid perceptions of  
unwarranted variation.
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